Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16981)	7/2/2004 9:28:20 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Blue>not meaning to rain on your parade. I have to disagree..."some". While I agree that enbrel has risk, I also have to say that enbrel has its place in treatments. Its a fine drug with risks that must be weighed vs benefits. Now that raptiva is out there there is more to weigh as indeed raptiva is a option that wasnt before. That said, I think the double dosing of enbrel is....a greater risk. Secondly, how many times to I have to tell you aboout COMBO use of raptiva allowing a lower dose od enbrel. What a bunch of ninnies. Instead of doubling the dose to get a greater enbrel effect , they should be looking at HALFING the enbrel dose (with raptiva) to get the even greater effect. Lastly, Its a SAD state of affairs when lawyers (and not the fda) start dictating to doctors what they can prescribe and in what sequence or face retribution & penalty. Its a big difference between malpractice & negligence verses the art of medicine which is still manytimes trial and error. What do you agree or disagree with ??? all IMO, no facts